SPONSORED CONTENT News of an electronic medical record (EMR) conversion often brings about palpable anxiety and anticipation as a covered […]
SPONSORED CONTENT The purpose of the 340B drug pricing program remains a contested question between 340B providers and some in […]
SPONSORED CONTENT It’s easy to remember the days before 340B ESP, when setting up of a wholesale account was an […]
SPONSORED CONTENT Stay ahead of the latest developments shaping the 340B landscape with Ted Slafsky, Publisher and CEO of 340B […]
SPONSORED CONTENT Introduction: Navigating Political Headwinds As the 2025 political season heats up, federally qualified health centers (FQHCs), hospitals, STD […]
SPONSORED CONTENT Across America, safety-net hospitals stand as a lifeline for millions. These institutions serve patients who often have nowhere […]
SPONSORED CONTENT The term “specialty medication” is often associated with a hefty price tag and numerous challenges related to claims […]
SPONSORED CONTENT As we endure Spring 2025, many covered entities (CEs) continue to perform their ordinary and necessary duties to […]
SPONSORED CONTENT Please join on us April 22nd at 1:00 p.m. EST for the third installment of RxParadigm’s 340B Clearinghouse […]
SPONSORED CONTENT At the 340B Coalition winter conference in February, two major topics were impossible to ignore: the growing interest […]